EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

M2 Macrophage‐Derived Galectin‐9 Enhances SLC1A5 Membrane Stability and Glutamine Metabolism to Promote Hepatocellular Carcinoma Progression

Yujing Guo, Qian Huang, Sha Yin, Lunbiao Gan, Zehua Liu, Jiaqi Ning, Yu Lu, Wenxiu Ru, Fengze Nie, Sijia Di, Siyu Yao, Huanhuan Wan and 4 more

Advanced Science · 2026-11-18

DOI: 10.1002/advs.78682 ↗

At a glance

Journal article in Advanced Science, published online on 2026-11-18. Written by Yujing Guo and 15 co-authors. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

SantraukaBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths globally. Current therapeutic options remain limited by poor efficacy, and there is an urgent need to identify new therapeutic targets and strategies. Metabolic reprogramming is a hallmark of HCC progression, and intercellular crosstalk within the tumor microenvironment (TME) critically shapes tumor cell metabolism. However, the cell types and mechanisms regulating HCC cell metabolism remain largely unclear. In this study, by combining single‐cell RNA sequencing (scRNA‐seq) and spatial transcriptomic data, we found that M2‐like tumor‐associated macrophages (TAMs) were associated with highly metabolic HCC cells. Using intercellular protein interaction detection (ICPID), a proximity‐labeling method developed in this study, we identified that Galectin‐9 (Gal‐9), highly expressed and secreted by M2 macrophages, is a ligand for the glutamine transporter SLC1A5 on HCC cells. This glycan‐dependent interaction promoted the membrane localization of SLC1A5, thereby enhancing glutamine uptake and metabolism to promote HCC growth. Gal‐9 neutralization or SLC1A5 inhibition suppressed glutamine metabolism and tumor‐promoting phenotypes both in vitro and in vivo. Our study shows that M2 macrophage‐derived Gal‐9 can promote HCC progression by directly enhancing glutamine metabolism in HCC cells, and that the Gal‐9‐SLC1A5 axis may serve as a new therapeutic target for HCC treatment.

Funding

  • National Natural Science Foundation of China

Cite

APA

Guo, Y., Huang, Q., Yin, S., Gan, L., Liu, Z., Ning, J., Lu, Y., Ru, W., Nie, F., Di, S., Yao, S., Wan, H., Liu, L., Yang, F., Qin, W., & Wen, W. (2026). M2 Macrophage‐Derived Galectin‐9 Enhances SLC1A5 Membrane Stability and Glutamine Metabolism to Promote Hepatocellular Carcinoma Progression. Advanced Science. https://doi.org/10.1002/advs.78682

Vancouver

Guo Y, Huang Q, Yin S, Gan L, Liu Z, Ning J, et al. M2 Macrophage‐Derived Galectin‐9 Enhances SLC1A5 Membrane Stability and Glutamine Metabolism to Promote Hepatocellular Carcinoma Progression. Advanced Science. 2026. doi:10.1002/advs.78682

BibTeX
@article{Guo2026,
  author = {Guo, Yujing and Huang, Qian and Yin, Sha and Gan, Lunbiao and Liu, Zehua and Ning, Jiaqi and Lu, Yu and Ru, Wenxiu and Nie, Fengze and Di, Sijia and Yao, Siyu and Wan, Huanhuan and Liu, Le and Yang, Fa and Qin, Weijun and Wen, Weihong},
  title = {M2 Macrophage‐Derived Galectin‐9 Enhances SLC1A5 Membrane Stability and Glutamine Metabolism to Promote Hepatocellular Carcinoma Progression},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78682}
}
Start for free →